Search results: (10000)
News Study AMPLIFY Confirmed Safety and Efficacy of Fixed Combination Aclidinium/Formoterol in COPD Therapy
The randomized double-blind phase III AMPLIFY study compared the efficacy of a fixed combination of formoterol/aclidinium with monotherapy of the individual components or with tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
News Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
News Bite-Sized Pieces from EHA 2021: Two New Findings on T-Cell Lymphoma
Can a molecule that is crucial for the sensitivity of adult T-cell lymphoma or leukemia (ATLL) to NK cell cytotoxicity be identified? And what conclusions were drawn from the testing of an antibody specific for TRBC1 in the investigation of T-lymphoproliferative disorders? These topics were also covered at the EHA 2021 congress, in the electronic poster presentation section.
News HAE and its Management in Pediatric Patients
Hereditary angioedema (HAE) can be encountered in the emergency room as well as in specialist practices. Patients with this rare disease are often incorrectly diagnosed with other, more common conditions, and it can take many years before they receive the correct diagnosis. This is because the symptoms of HAE overlap with those of other illnesses. What should pediatricians, otolaryngologists, and gastroenterologists be aware of? To provide a better understanding of HAE symptoms from the perspective of various specialties and emphasize the importance of interdisciplinary collaboration for the correct diagnosis and care of patients with HAE, a professional webinar was held. We have prepared a summary of the most important points for you.
News Retention – An Overlooked Parameter of Incontinence Products
In the Czech Republic and other European countries, the main criterion when choosing an incontinence product, apart from its size, is primarily absorption. This defines the amount of fluid the product can hold in its absorbent core, but it does not tell anything about its retention capability. What is retention and why is it important to know?
News Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
In a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.
News Heart Failure in Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd at 5 PM.
You can find more information in the attached invitation below.
You can find more information in the attached invitation below.
News What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?
During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).
News Impact of Primary Tumor Location and Early Regression on Survival in Patients with Metastatic CRC
Results from recent clinical studies suggest the prognostic significance of the primary tumor location on the survival of patients with metastatic colorectal cancer (mCRC). A retrospective analysis of data from a single-arm open-label phase II clinical trial evaluated the impact of primary tumor location and its early regression (ETS - early tumor shrinkage) on the survival of patients with mCRC who received a combination of chemotherapy (FOLFIRI regimen) and targeted biological therapy (panitumumab).
News Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often associated with subprophylactic anti-Xa activity in high-risk patients. A recently published study evaluated the efficacy and safety of administering enoxaparin in doses adjusted according to the measured anti-Xa activity.
News Presence of Risk Factors Associated with Colectomy in Patients with Ulcerative Colitis in Studies with Tofacitinib
One of the important goals of active ulcerative colitis therapy is the prevention of colectomy. A clinical study, the results of which were recently presented at the Vienna UEG (United European Gastroenterology) congress, evaluated the association of risk factors and the use of tofacitinib with colectomy in patients with active ulcerative colitis in the OCTAVE clinical trial program.
News Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis
Data from randomized clinical trials have shown that romiplostim is an effective medication for many patients not only with acute or persistent immune thrombocytopenia (ITP) but also for much more complicated patients with chronic ITP. In April 2021, data on the efficacy and safety of romiplostim from European clinical practice were published.
News Study PLATON: romiplostim in patients with ITP in real clinical practice
Recently, the results of the PLATON study with romiplostim, which was conducted in Central and Eastern European countries including the Czech Republic, were published. It was an observational non-interventional cohort study from real practice, and romiplostim was used within its approved indication.
News Adequate Compensation of a Hypertensive Patient According to Current ESC Guidelines – Case Study
A 65-year-old man, hypertensive, visits the general practitioner for a check-up. He reports recent shortness of breath during mild exertion (walking up stairs). Two months ago, he had acute sinusitis, for which he was prescribed antibiotics (penicillin V) by a specialist. He experiences hip pain and suffers from a runny nose in the spring (allergy?). He has been treated for hypertension for approximately 8 years.
News Sports in People with Hemophilia – Possible and Safe
Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.
News Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.
News Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension
Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor, is a widely used antihypertensive. The PPAR-γ receptor plays a role in the genesis of osteoblasts and osteoclasts, and antidiabetic drugs from the thiazolidinedione group, which act as agonists of this receptor, have a known inhibitory effect on bone metabolism and increase the risk of non-traumatic fractures. Knowledge regarding the potential similar effects of telmisartan is limited. The following study compared the effects of telmisartan and losartan (an AT1 blocker without agonistic effect on PPAR-γ) on bone turnover markers in patients with newly diagnosed hypertension.
News Safe Long-term Treatment of Nasal Symptoms in Patients with Perennial Allergic Rhinitis
In persistent allergic rhinitis, achieving symptom control is often difficult despite pharmacological treatment and minimizing contact with the allergen. Good efficacy in clinical studies has been shown with combined therapy of intranasal antihistamines with locally acting corticosteroids. The presented study evaluated the long-term safety profile and efficacy of a fixed combination of olopatadine with mometasone.
News ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?
In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic obstructive pulmonary disease (COPD) and its acute exacerbations (COPD AE). This topic was also well-represented in the e-poster presentations section. From that section, we select 3 studies whose conclusions are summarized below.
News N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with hemophilia B evaluated the long-term safety and effectiveness of this prophylactic modality.
News Current Treatment Options for Refractory/Relapsed CLL
How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review published in Acta Haematologica discusses the current therapeutic options for relapsed or refractory disease.
News Effectiveness of the Venetoclax/Rituximab Combination in the Treatment of CLL – 5-Year Follow-Up Data
At the virtual 62nd Annual Meeting of the American Society of Hematology (ASH), updated results of a clinical evaluation of the treatment of patients with refractory/relapsed chronic lymphocytic leukemia (R/R CLL) using venetoclax in combination with rituximab were presented.
News When to Switch to Second-Line Treatment for Primary Biliary Cholangitis?
In patients with primary biliary cholangitis (PBC), the response to ursodeoxycholic acid (UDCA) treatment is an important prognostic indicator. To identify patients with an insufficient response to this modality who require second-line therapy, the best practice is to assess the biochemical response to UDCA after 12 months of treatment. A validated and easy-to-use tool is the determination of serum alkaline phosphatase (ALP) activity and serum total bilirubin concentration. Although treatment response to UDCA is commonly checked after 12 months, a 6-month check has the same discriminatory value.